Clinical trial · Interventional
A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
NCT00463359CI-TRIAL-00000694unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine recurrence rates of nodular Basal Cell Carcinomas on the face removed with curettage and electrodessication (cautery) followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with curettage and electrodessication alone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| curettage and cautery | Procedure | — | UNRESOLVED |
| Imiquimod cream | Drug | Imiquimod | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Basal Cell Carcinoma recurrence rates in 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 49 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Well-defined primary, not previously treated nodulo-cystic BCC * Size of the lesions: ≤ 1cm diameter * Facial lesions * Patient compliance competent * Patient physically able to apply the treatment (cream) Exclusion Criteria: * Recurrent lesions * Superficial, morphoeic or pigmented BCC * Lesions close to vital structures; i.e. where C\&C is not considered a standard treatment (eyelids, inner canthus, free borders) * Lesions within 1 cm of the eyelids, nose, lips and hairline * Immunosuppressed patients * Women in childbearing age, pregnancy and breast-feeding * Ages \<50 or \>90 * Patients compliance incompetent * Patients physically incapable to apply the treatment (cream) * Patients with Gorlin Syndrome (nevoid Basal Cell Carcinoma syndrome)
References
Publications (0)
Data not yet available
No reference posted for this study.